



Figure 3






(B)








(A)



















AtNCED3 CPRD65	RASFIATAVSG-RACEGONTOPPLSSSGSSPLSYCS4EPHASAVTRKLNVSSALHTFPALH HISBASNTHENT PSPPFKOLPSTSSPTNLUPLRKTSSSHTTICSPOILHIPKQYQHTSTSTSTATTTEPPIK HISBASNTHENT PSPPFKOLPSTSSPTNLUPLRKTSSSHTTICSPOILHIPKQYQHTSTSTSTATTTEPPIK	61 75
AtNCED3	FPKQSSNSPATYVMPI—KAKESNTKQMIJHQIMAAHALDIMEDFLYSHEKLIHPLPKTADPJYQTAGMFAPYNEQP	134
CPRD65	TTTTTTTIPPRETNPI-SDTNQPLPQKIMPLQIMAAAHALDI-VET <u>ALYSHENHIPLPKTADPYQTAGMFAPY</u> HEHA	150
AtNCED3	vrrulpyvigk.pdst.kovyvrnganpl.hepvjghhefbodgmynavkfehglasyacrftithryvderdlorpy	2 <b>0</b> 9
CPRD65	adoglpyvigk.pdk.ditkovyvrnganpl.hepvjghhefbodgmynavkfynghasyacrftithr.sgekslorpy	225
AtNCED3	FPKAIGELHGH)GIARLHLFYARAAGIYOPAHGIGVANAGLYYFNGHLAMSEDDLPYGVDTTPHODLTTVGR	284
CPRD65	FPKAIGELHGH)GIARLHLFYARGLHGLYDSGGHGVANAGLYYFNHLLAMSEDDLPYHVFLTPHODLJTVGRY	300
AtNCED3	OF GOLLSTMIAHPKLOPS GGL.HALSYDVYSKPYLKYFRSPDGKSPDVETLLDCPTMHOFAITENFVWPD	359
CPRD65	DF GGL.HSTMIAHPKLOPYGGL.HALSYDVTCKPYLKYFRSPDGKSPDVETFLKSPTMHOFAITENFVWPD	375
AtNCED3	QQWFKL  ENI  GGSPVVYDKNK  AFGGL  TRYAEDSSNIK  TDAPDCFCFHLIMAWEEPET  EVVVIGSCHTP	434
CPRD65	QQVYFKL  ENI  GGSPVVYDKNK  SRFGIL  RVJAKDANAM  RIDAPDCFCFHLIMAWEEPET  EVVVIGSCHTPA	450
AtNCED3	DSIFNESUENLKSVLSEIRLINLYTGESTRAPIISNEDOTVALEAGAVARNALGRKTAFAYLALAEPHAKVSGFAK	509
CPRD65	DSIFNESUENSVLSEIRLINLYTGESTRAPIISDAGGVANLEAGAVARNALGRKTAFAYLALAEPHAKVSGFAK	524
AtNCED3	vol) tigevkkihuyednryggeplelpieggebedikyti. Ipvhoekinkselqivnaysleveatyklpsrvpygf	584
CPRD65	vol) sgevkkynygerhyggeplelpi, ngmedikyti. Ipvhoekinkselqivnamilkueas iklpsrvpygf	598
AtNCED3	HGTFILSKOLYKOV	599
CPRD65	HGTFIHSKOLYKOV	612














A B WT C D
Overexpression Wild Expression

type

inhibition

